ReviewZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2025
[Application of the variant allele frequency of myeloid-associated gene mutations in myelodysplastic syndrome].
Review in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myelodysplastic syndrome (MDS) is a heterogeneous clonal myeloid malignancy with a variable prognosis. Some myeloid-related gene alterations have been found to be associated with the diagnosis and prognosis of MDS. As a result, multiple myeloid-related gene mutations have been added to International Working Group for Prognosis in MDS (IWG-PM) and other MDS prognosis evaluation systems as diagnostic and prognostic indications. Further research using the variable allele frequency (VAF) detection technique demonstrated that myeloid-related genes evolve dynamically during the course of MDS with some regularity. Furthermore, significant relevance have been found between the VAF evolution of particular myeloid-related genes and MDS subtypes, risk classification, and prognosis. This article provides an overview of the application of VAF of myeloid-related gene mutations in MDS research, highlighting the critical role of gene mutation VAF in MDS subtype categorization, risk stratification, and therapy response assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.